PeptidePros

Compare · Head-to-head

GHRP-6 vs MOTS-c.

Evidence, risk, regulatory flags, cost, and vendor coverage compared side by side. We don’t sell peptides — we help you choose between them.

Which should you research first?

Start with GHRP-6, then use the table to confirm fit.

GHRP-6 is the cleaner first read based on the current evidence, risk, and regulatory data stored for this pair. The right answer can still change if your goal, sport testing status, vendor constraints, or monitoring tolerance makes the other option a better fit.

Comparison next step

Personalize this head-to-head.

Take the quiz before converting a comparison into a compound, vendor, or protocol decision.

01· Subject

GHRP-6

GH secretagogue with phase I PK data in humans. FDA has flagged compounding safety concerns.

Tier Bhigh risk

02· Subject

MOTS-c

Mitochondrial-derived peptide studied in mouse models for metabolic homeostasis and insulin sensitivity.

Tier Chigh risk

01 · At a glance

Decision factorGHRP-6MOTS-c
Primary fitmuscle growth & strength and fat loss & metabolism comparisonsfat loss & metabolism and longevity & anti-aging comparisons
EvidenceTier BTier C
Riskhighhigh
Experience levelintermediateadvanced
Budget tiermidpremium
Administration routeintravenous, subcutaneoussubcutaneous

02 · Use case & timing

Decision factorGHRP-6MOTS-c
Goal fitMuscle Growth & Strength, Fat Loss & Metabolism, GH Axis OptimizationFat Loss & Metabolism, Longevity & Anti-Aging
What users compare it forGH-axis stimulation; appetite stimulation commonly reported.Preclinical: improved insulin sensitivity, metabolic regulation, exercise performance in mice.
Onset timelineAcute GH response after IV dosing; PK shows hours-scale elimination.Metabolic endpoints assessed over days to weeks in mice; exercise performance improvements after ~10 days.
Main tradeoffEvidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter.Potential upside comes with much more safety and screening caution than lower-risk alternatives.

03 · Safety & restrictions

Decision factorGHRP-6MOTS-c
Adverse effectsImmunogenicity/impurity concerns (FDA); cortisol effects; decreased insulin sensitivity; glucose metabolism risk.FDA: no identified human exposure data; significant immunogenicity/characterization risks.
ContraindicationsNo formal label.No human data.
Interaction notesFlag glucose metabolism risk and endocrine-axis spillover as monitoring concerns.Unknown.
Regulatory statusNot approvedNot approved
FDA flagFDA compounding cautionFDA compounding caution
WADA statusWADA S2Status unclear

04 · Age & monitoring

Decision factorGHRP-6MOTS-c
Supported age rangesNo age guidance yetNo age guidance yet
Life-stage noteNot yet documentedNot yet documented
Monitoring burdenNot specifiedNot specified
Follow-up cadenceNot yet documentedNot yet documented

05 · Cost & sourcing

Decision factorGHRP-6MOTS-c
Typical cycle cost€35.76€33.02
Estimated monthly cost€17.88€33.02
Cost confidenceHigh confidenceHigh confidence

06 · Before you buy

Decision factorGHRP-6MOTS-c
Tracked vendor listings1 listing3 listings
Sourcing noteTracked product pages are available, which makes it easier to review the listing before you click out.Product format varies by listing, so double-check route, concentration, and presentation.
Stack-friendly?Usually stack-friendlyUsually stack-friendly

Sources and review notes

  1. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15

    Used for FDA compounding-risk context and peptide safety flags.

  2. The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15

    Used for athlete-facing WADA risk and peptide-class restrictions.

  3. Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15

    Used for broad peptide-therapeutics background and evidence framing.

Still deciding

Get a plan tailored to you.

The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.